1. Home
  2. ADVM vs NEUE Comparison

ADVM vs NEUE Comparison

Compare ADVM & NEUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • NEUE
  • Stock Information
  • Founded
  • ADVM 2006
  • NEUE 2015
  • Country
  • ADVM United States
  • NEUE United States
  • Employees
  • ADVM N/A
  • NEUE N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • NEUE
  • Sector
  • ADVM Health Care
  • NEUE
  • Exchange
  • ADVM Nasdaq
  • NEUE NYSE
  • Market Cap
  • ADVM 59.5M
  • NEUE 61.2M
  • IPO Year
  • ADVM 2014
  • NEUE 2021
  • Fundamental
  • Price
  • ADVM $2.41
  • NEUE $6.84
  • Analyst Decision
  • ADVM Strong Buy
  • NEUE Hold
  • Analyst Count
  • ADVM 5
  • NEUE 1
  • Target Price
  • ADVM $26.40
  • NEUE $7.00
  • AVG Volume (30 Days)
  • ADVM 430.7K
  • NEUE 7.2K
  • Earning Date
  • ADVM 05-14-2025
  • NEUE 05-08-2025
  • Dividend Yield
  • ADVM N/A
  • NEUE N/A
  • EPS Growth
  • ADVM N/A
  • NEUE N/A
  • EPS
  • ADVM N/A
  • NEUE N/A
  • Revenue
  • ADVM $1,000,000.00
  • NEUE $907,349,000.00
  • Revenue This Year
  • ADVM N/A
  • NEUE $33.99
  • Revenue Next Year
  • ADVM $42.58
  • NEUE $5.90
  • P/E Ratio
  • ADVM N/A
  • NEUE N/A
  • Revenue Growth
  • ADVM N/A
  • NEUE N/A
  • 52 Week Low
  • ADVM $1.78
  • NEUE $3.79
  • 52 Week High
  • ADVM $10.14
  • NEUE $7.66
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 40.10
  • NEUE 51.38
  • Support Level
  • ADVM $2.15
  • NEUE $6.66
  • Resistance Level
  • ADVM $2.33
  • NEUE $6.87
  • Average True Range (ATR)
  • ADVM 0.23
  • NEUE 0.10
  • MACD
  • ADVM 0.04
  • NEUE -0.01
  • Stochastic Oscillator
  • ADVM 52.58
  • NEUE 48.28

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About NEUE NEUEHEALTH INC

NeueHealth Inc is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare. It consists of two reportable segments: NeueCare - it's a value-driven care delivery business that manages risk in partnership with external payors and serves all populations across The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. NeueSolutions - it's a provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers to thrive in performance-based arrangements.

Share on Social Networks: